This is now nothing more than a shell company...some cash, a public listing, a handful of employees (pushing paper in an office) and a product that has been outlicensed for China. Nothing more.
All they can do now is to in-license some products and build some value. They may as well also change their name...PAB was a monoclonal Ab company with both preclinical operations and a clinical-stage pipeline, actively engaged in clinical trials...it is definitely not that anymore.
This is now nothing more than a shell company...some cash, a...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $5.431K | 1.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 26519870 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7889760 | 12 |
View Market Depth
| Last trade - 11.23am 15/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |